FibroGen (NASDAQ: FGEN) reported Q4 EPS of ($0.57), $0.13 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $27.1 million versus the consensus estimate of $38.78 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.